Fractalkine-CX3CR1 Axis in Periodontal Therapy

Fractalkine and CX3CR1 Dynamics in Gingivitis and Periodontitis Before and After Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07307144

Enrollment

Registered

2025-12-29

Start date

2022-05-15

Completion date

2023-12-10

Last updated

2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis, Inflammation Biomarkers, Periodontitis

Keywords

periodontitis, gingivitis, gingival crevicular fluid

Brief summary

This study aimed to evaluate gingival crevicular fluid (GCF) levels of fractalkine/CX3CL1 and CX3CR1 in patients with gingivitis and periodontitis before and after non-surgical periodontal therapy.

Detailed description

Thirty stage 3 periodontitis, thirty gingivitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; gingivitis and periodontitis patients underwent non-surgical periodontal treatment, and GCF samples were collected at baseline and at 1 and 3 months after treatment. CX3CL1 and CX3CR1 were determined by ELISA.

Interventions

OTHERNon-surgical periodontal treatment

Scaling and root planing, oral hygiene education and motivation.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 47 Years

Healthy volunteers

Yes

Inclusion criteria

1. 25-50 years of age 2. having at least 20 natural teeth, excluding third molars 3. having no systemic disease 4. non-smokers 5. criteria for healthy control group: BOP \< 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction 6. criteria for stage 3 periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.

Exclusion criteria

1. having any systemic diseases, 2. smoking 3. current pregnancy or lactation 4. a history of periodontal treatment in the past 6 months 5. using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.

Design outcomes

Primary

Measure	Time frame	Description
Changes in the levels of biochemical parameters	Baseline and 1 and 3 months after treatment	The levels of Fractalkine and CX3CR1 before and after periodontal treatment in gingivitis and periodontitis patients.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026